BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MannKind Corporation readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies MannKind Corporation's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07224321-323@assetmemo.bio
DTSTAMP:20261121T010148Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Afrezza: Phase 2 readout est. (NCT07224321)
DESCRIPTION:Afrezza\, phase 2\, Type 1 Diabetes.\nStudy: INHALE-1st: Afrezz
 a® For Youth With Newly-Diagnosed Type 1 Diabetes\nEstimated primary comp
 letion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 frezza#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07224321
URL:https://assetmemo.bio/drug/afrezza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
